Busulfan

Generic Name: Busulfan

Brand Names: Busulfex, Myleran, Busulfan Fresenius Kabi

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₄O_₆S_₂

CAS Number: 55-98-1

Unique Ingredient Identifier: G1LN9045DK

Background: Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...

Indication: For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...

Associated Conditions: Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004231

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: III. Medizinische Klinik Mannheim

Target Recruit Count: 1000

Registration Number: NCT00025402

Locations: 🇩🇪
Tumorzentrum Berlin-Moabit, Berlin, Germany
🇩🇪
Wenckebach - Krankenhaus, Berlin, Germany
🇩🇪
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany

and more 175 locations

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00014469

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-20

Lead Sponsor: Duke University

Target Recruit Count: 20

Registration Number: NCT00003462

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 720

Registration Number: NCT00006363

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004899

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004907

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004181

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004896

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-04

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Registration Number: NCT00008190

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy